Filing summary
Entity mismatch: The supplied filing is Avista Healthcare Public Acquisition Corp.’s Form 10-K, not an Organogenesis Holdings Inc. filing. It reports fiscal year ended December 31, 2017; the summary below reflects the filing provided.
Business context and reporting period
Avista was a Cayman Islands blank-check company seeking a business combination, with a focus on North American or European healthcare businesses. It had no operating business and generated no revenue through year-end. The 2017 annual report was filed March 14, 2018.
Financial results and liquidity
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | None | None |
| Formation and operating costs | $4.592 million | $208,698 |
| Interest and dividend income | $2.498 million | None |
| Net loss | $2.094 million | $208,698 |
| Basic and diluted loss per share | $0.48 | $0.03 |
| Cash used in operating activities | $586,604 | $562,233 |
At December 31, 2017, total assets were $312.792 million, including $312.498 million in the trust account; total liabilities were $14.779 million and shareholders’ equity was $5.000 million. Cash outside the trust was $125,886, and working capital was a deficit of $3.634 million. The trust balance included $10.850 million of deferred underwriting commissions payable if a business combination closes. The company reported no long-term debt or off-balance-sheet financing arrangements. The filing does not provide meaningful operating margins because the company had no revenue-generating operations.
Material changes and notable events
- Net loss increased to $2.094 million from $208,698, primarily as operating and formation costs rose; trust-account income partly offset those costs.
- The company signed a proposed business combination with Envigo in August 2017, but mutually terminated the agreement on February 14, 2018. No transaction was completed.
- Accrued expenses included $3.774 million of vendor invoices deferred until a business combination or liquidation. The company had borrowed $100,000 under a non-interest-bearing Sponsor note, with borrowing capacity up to $300,000.
Outlook, risks, and contingencies
Management said it believed available resources were sufficient to pursue a business combination through October 14, 2018, the 24-month deadline after the IPO closing. If no combination were completed by then, the company was required to wind up and redeem public shares from the trust, subject to creditor claims and applicable law; warrants would expire worthless. Management cautioned that cash outside the trust might not cover expenses through the deadline and additional financing might be needed.
- Trust funds could be reduced by creditor claims; the Sponsor’s indemnity is limited and its ability to meet it was not verified by the company.
- Public-share redemptions could constrain deal funding, while the short deadline could weaken the company’s negotiating position or limit due diligence.
- Management disclosed potential conflicts because officers and directors had other Avista-related duties and investment interests.
- NASDAQ notified the company that it had failed to hold a required annual meeting; it received an extension to June 29, 2018 to regain compliance.
- Management reported effective disclosure controls and internal control over financial reporting. The auditor issued an unqualified opinion on the financial statements; it did not audit internal controls.
Key facts for investors to verify
- Confirm the intended issuer: this filing is for Avista Healthcare Public Acquisition Corp., not Organogenesis Holdings Inc.
- Check subsequent filings for the Envigo termination, any replacement transaction, and the company’s eventual status relative to its October 14, 2018 deadline.
- Verify trust-account proceeds, redemption amounts, deferred underwriting commissions, and any creditor claims or Sponsor indemnity obligations.
- Check whether the company held the required annual meeting and regained NASDAQ listing compliance by the extended deadline.